Shruti Patel, MD

All Publications

• Redefining Available Therapy in Oncology Accelerated Approval Decisions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology Patel, S. R., Ramachandran, M., Ai, A., Chen, C. T. 2024: JCO2400892

  Abstract

  When weighing rapid approval for follow-on drugs, should @FDAOncology recognize the drugs that came before?

  View details for DOI 10.1200/JCO.24.00892

  View details for PubMedID 39454117

• Lung Cancer in Women: The Past, Present, and Future. Clinical lung cancer Florez, N., Kiel, L., Riano, I., Patel, S., DeCarli, K., Dhawan, N., Franco, I., Odai-Afotey, A., Meza, K., Swami, N., Patel, J., Sequist, L. V. 2023

  Abstract

  Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females. Current lung cancer treatment and screening guidelines do not incorporate sex-specific differences and physicians also often do not account for gender differences when choosing treatments or discussing survivorship needs. To best provide targeted treatment approaches, greater representation of women in lung cancer clinical trials and further research is necessary. Clinicians should understand the unique factors and consequences associated with lung cancer in women; thus, a holistic approach that acknowledges environmental and societal factors is necessary.

  View details for DOI 10.1016/j.cllc.2023.10.007

  View details for PubMedID 37940410

• Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy. Cancers Patel, S. R., Das, M. 2023; 15 (16)

  Abstract

  Small cell lung cancer is an aggressive subtype of lung cancer with limited treatment options. Precision medicine has revolutionized cancer treatment for many tumor types but progress in SCLC has been slower due to the lack of targetable biomarkers. This review article provides an overview of emerging strategies for precision therapy in SCLC. Targeted therapies include targeted kinase inhibitors, monoclonal antibodies, angiogenesis inhibitors, antibody-drug conjugates, PARP inhibitors, and epigenetic modulators. Angiogenesis inhibitors and DNA-damaging agents, such as PARP and ATR inhibitors, have been explored in SCLC with limited success to date although trials are ongoing. The potential of targeting DLL3, a NOTCH ligand, through antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapy, has opened up new therapeutic options moving forward. Additionally, new research in epigenetic therapeutics in reversing transcriptional repression, modulating anti-tumor immunity, and utilizing antibody-drug conjugates to target cell surface-specific targets in SCLC are also being investigated. While progress in precision therapy for SCLC has been challenging, recent advancements provide optimism for improved treatment outcomes. However, several challenges remain and will need to be addressed, including drug resistance and tumor heterogeneity. Further research and biomarker-selected clinical trials are necessary to develop effective precision therapies for SCLC patients.

  View details for DOI 10.3390/cancers15164016

  View details for PubMedID 37627044

• Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Translational lung cancer research Patel, S. R., Neal, J. W. 2023; 12 (7): 1631-1635

  View details for DOI 10.21037/tlcr-23-273

  View details for PubMedID 37577327

  View details for PubMedCentralID PMC10413020

• Enhancing Patient Retention in Clinical Trials-Strategies for Success. JAMA oncology Idossa, D., Patel, S., Florez, N. 2023

  View details for DOI 10.1001/jamaoncol.2023.1341

  View details for PubMedID 37347478

• Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? TRANSLATIONAL LUNG CANCER RESEARCH Patel, S. R., Neal, J. W. 2023

  View details for DOI 10.21037/tlcr-23-273

  View details for Web of Science ID 001015487200001

• What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants Idossa, D., Manana, A., Horiguchi, M., Suero-Abreu, G., Franco, I., Borrero, M., Patel, S., Dhawan, N., Florez, N. LIPPINCOTT WILLIAMS & WILKINS. 2023

  View details for Web of Science ID 001053772003267

• Race/Ethnicity and Gender Representation in Hematology and Oncology Editorial Boards: What is the State of Diversity? The oncologist Patel, S. R., Riano, I., Abuali, I., Ai, A., Geiger, G., Pimienta, J., Ramirez Roggio, A., Dhawan, N., Dizman, N., Lizette Salinas, A., Pomares-Millan, H., Florez, N. 2023

  Abstract

  Women and underrepresented groups in medicine hold few academic leadership positions in the field of hematology/oncology. In this study, we assessed gender and race/ethnicity representation in editorial board positions in hematology/oncology journals.Editorial leadership board members from 60 major journals in hematology and oncology were reviewed; 54 journals were included in the final analysis. Gender and race/ethnicity were determined based on publicly available data for Editor-in-Chief (EiC) and Second-in-Command (SiC) (including deputy, senior, or associate editors). Descriptive statistics and chi-squared were estimated. In the second phase of the study, editors were emailed a 4-item survey to self-identify their demographics.Out of 793 editorial board members, 72.6% were men and 27.4% were women. Editorial leadership were non-Hispanic white (71.1%) with Asian editorial board members representing the second largest majority at 22.5%. Women comprised only 15.9% of the EiC positions (90% White and 10% Asian). Women were about half as likely to be in the EiC position compared with men [pOR 0.47 (95% CI, 0.23-0.95, P = .03)]. Women represented 28.3% of SiC editorial positions. Surgical oncology had the lowest female representation at 2.3%.Women and minorities are significantly underrepresented in leadership roles on Editorial Boards in hematology/oncology journals. Importantly, the representation of minority women physicians in EiC positions is at an inexorable zero.

  View details for DOI 10.1093/oncolo/oyad103

  View details for PubMedID 37119268

• Disparities in cancer care-A call to action. Cancer cell Abuali, I., Patel, S., Kiel, L., Meza, K., Florez, N. 2023; 41 (1): 1-4

  Abstract

  Disparities in cancer care disproportionately impact minority groups, members of which face challenges in accessing high-quality cancer care, remain underrepresented in clinical trials, and experience significant financial toxicity and discrimination during their cancer journey. Diversifying our workforce, improving access to trials, and allocating research funding for equitable initiatives should be prioritized.

  View details for DOI 10.1016/j.ccell.2022.11.003

  View details for PubMedID 36626866

• Inequity in care delivery in cardio-oncology: dissecting disparities in underrepresented populations. Frontiers in oncology Patel, S. R., Suero-Abreu, G. A., Ai, A., Ramachandran, M. K., Meza, K., Florez, N. 2023; 13: 1124447

  Abstract

  It is well known that patients with cancer have a significantly higher cardiovascular mortality risk than the general population. Cardio-oncology has emerged to focus on these issues including risk reduction, detection, monitoring, and treatment of cardiovascular disease or complications in patients with cancer. The rapid advances in early detection and drug development in oncology, along with socioeconomic differences, racial inequities, lack of support, and barriers to accessing quality medical care, have created disparities in various marginalized populations. In this review, we will discuss the factors contributing to disparities in cardio-oncologic care in distinct populations, including Hispanic/Latinx, Black, Asian and Pacific Islander, indigenous populations, sex and gender minorities, and immigrants. Some factors that contribute to differences in outcomes in cardio-oncology include the prevalence of cancer screening rates, genetic cardiac/oncologic risk factors, cultural stressors, tobacco exposure rates, and physical inactivity. We will also discuss the barriers to cardio-oncologic care in these communities from the racial and socioeconomic context. Appropriate and timely cardiovascular and cancer care in minority groups is a critical component in addressing these disparities, and there need to be urgent efforts to address this widening gap.

  View details for DOI 10.3389/fonc.2023.1124447

  View details for PubMedID 37361603

• Optimal timing and interval of imaging for metastatic breast cancer. Patel, S., Itakura, H., Sledge, G. W. LIPPINCOTT WILLIAMS & WILKINS. 2022

  View details for Web of Science ID 000863680300340

• Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational lung cancer research Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., Zhang, L., Feng, Y., Ge, X., Zhai, J., Jiang, M., Zhou, X., Simone, C. B., Neal, J. W., Patel, S. R., Yan, X., Hu, Y., Wang, J. 2022; 11 (6): 1119-1131

  Abstract

  Background: Although the prognosis of non-small cell lung cancer (NSCLC) can be assessed based on pathological type, disease stage and inflammatory indicators, the prognostic scoring model of NSCLC still needs to improve. HDAC11 is associated with poor prognosis of partial tumors, but its prognostic relationship with NSCLC is poorly understood. In this study, the role of HDAC11 in NSCLC was studied to evaluate relationship with disease prognosis and potential therapeutic target.Methods: The clinicopathological and paracancerous tissues of patients with NSCLC primarily diagnosed in Tangdu Hospital from 2009 to 2013 were collected. Follow-up of patients were made every three months and the last follow-up period was December 2018. The expression of HDAC11 was assessed by immunohistochemistry (IHC). Then, weighted gene co-expression network analysis (WGCNA) was used to analyze the relationship between HDAC11 expression and the prognosis of lung adenocarcinoma (LUAD) patients. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Kaplan-Meier plotter database was used to verify the connection between hub genes and tumor stage and prognosis. We accessed the relationship between HDAC11 expression and clinicopathological features, and impact on the prognosis.Results: The study assessed 326 patients with NSCLC. Compared with adjacent tissues, HDAC11 expression was upregulated (HR =1.503, 95% CI: 1.172 to 1.927, P=0.001). Kaplan-Meier survival analyses showed that HDAC11 expression was closely related to OS of NSCLC patients (P=0.0011). Univariate and multivariate analyses showed that the independent risk factors of OS were clinical stage, HDAC11 expression, and HDAC11 differentiation (all P≤0.001). HDAC11 was significantly associated with prognosis in LUAD. A total of 1,174 differential genes and WGCNA were obtained to construct a co-expression network in LUAD. The GO and KEGG pathway enrichment analyses showed the relevance with staphylococcus aureus infection, NOD-like receptor signaling pathway, and others. The results of LUAD survival analysis showed that HDAC11-related genes NKX2-5 and FABP7 were significantly associated with LUAD prognosis.Conclusions: The high expression of HDAC11 is related to the poor prognosis of LUAD, and it is expected to become a therapeutic target and prognostic evaluation therapy for LUAD in the future. However, the relevant results need to be further studied and verified.

  View details for DOI 10.21037/tlcr-22-403

  View details for PubMedID 35832445

• Disparities in Cardio-Oncology Care in the Hispanic/Latinx Population. JCO oncology practice Suero-Abreu, G. A., Patel, S., Duma, N. 2022; 18 (5): 404-409

  View details for DOI 10.1200/OP.22.00045

  View details for PubMedID 35544659

• The Matilda Effect: Underrecognition of Women in Hematology and Oncology Awards ONCOLOGIST Patel, S. R., St. Pierre, F., Velazquez, A. I., Ananth, S., Durani, U., Anampa-Guzman, A., Castillo, K., Dhawan, N., Oxentenko, A. S., Duma, N. 2021

  Abstract

  The proportion of women in the field of hematology and oncology (H&O) has increased over recent decades, but the representation of women in leadership positions remains poor. In an effort to close the gender gap in academia, it is important to report on such inequities in hopes to close these gaps and improve career development.We conducted a retrospective, observational study of published award recipients from 1994 to 2019 from the seven major H&O societies in the world. Gender was determined based on publicly available data. The χ2 and Cochran-Armitage tests were used for data analysis.Of the 1,642 awardees over the past 26 years, 915 met inclusion criteria. Award recipients were overwhelmingly men (77.9%) and non-Hispanic White (84.7%). Women awardees received 30.3% of the humanistic and education-related awards, whereas only receiving 16.0% of basic science awards (p < .01). Women represent 35.6% of all hematologists and oncologists but only received 24.0% of awards given to these physicians (p = .004). Black, Hispanic, and Asian awardees represented 3.7%, 3.3%, and 6.8% of the total awardees, respectively.From 1994 to 2019, women were less likely to receive recognition awards from the seven major H&O societies studied compared with men. We also observed a considerably low proportion of minority awardees across all oncology subspecialties. Further studies examining how selection criteria favor either gender would be warranted in order to achieve equal representation in academic awards.In this study, women and minority groups were found to be underrepresented amongst award recipients. Significant disparities were seen in disciplines that have been historically male predominant, such as basic sciences. As awards on an international level enhance academic resumes and assist with career advancement, it is important that awards are being given in an equitable manner. First steps to promote diversity and inclusion in academic medicine is reporting of gender and racial disparities in various areas of academia.

  View details for DOI 10.1002/onco.13871

  View details for Web of Science ID 000671160700001

  View details for PubMedID 34157172